Exercise of Broker Option and Total Fundraise
Total Fundraise of £11.6 million
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), announces that further to the Fundraise announced on 7 July 2020, Numis Securities Limited has exercised the Broker Option in respect of 2,875,000 new Ordinary Shares (the "Broker Option Shares"), raising gross proceeds of approximately £0.35 million for the Company.
The Broker Option Shares are being issued at a price of 12p per share (being the Placing Price) and will be issued on the same terms and conditions as the Firm Placing Shares pursuant to the Placing.
Application will be made to the London Stock Exchange for the 2,875,000 Broker Option Shares to be admitted to trading on AIM. Admission of the Broker Option Shares to trading on AIM is expected to take place at 8.00am on 22 July 2020.
Following the exercise of the Broker Option in respect of 2,875,000 Broker Option Shares, the Company announces that the Broker Option is now complete with a total of 14,079,165 shares exercised, raising gross proceeds of approximately £1.69 million for the Company in aggregate.
With the completion of the Broker Option, and subject to admission of the Firm Placing Shares, Subscription Shares, Retail Shares and the Broker Option Shares, the Company can confirm that a total of £11.6 million in gross proceeds has been raised; comprising of a Firm Placing of £6.3 million, a Subscription of £2.8 million, a retail offer via the PrimaryBid Platform of £750k and £1.69 million via the Broker Option.
Following the admission of the Firm Placing Shares, Subscription Shares, Retail Shares and the Broker Option Shares, the Company will have a total of 419,024,611 Ordinary Shares in issue.
Capitalised terms used in this announcement have the meanings given to them in the announcement of the Fundraise dated 7 July 2020.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.